A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
15 Years to 70 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of ATL was made based on seropositivity for HTLV-I by either enzyme-linked immunosorbent assay or particle agglutination assay, and histologically- and/or cytologically-proven peripheral T-cell malignancy
Aggressive ATL, i.e., acute-, lymphoma- or unfavorable chronic-type ATL
Aged 15-69 years
No prior chemotherapy or radiotherapy
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3 or 4 as a result of hypercalcemia
Preserved organ (bone marrow, liver, kidney, heart and lung) functions
All patients were required to provide written informed consent
Diabetes mellitus necessitating treatment with insulin
Active systemic infection
Cardiac disorders expected to become worse as a result of the DOX-containing regimen
Acute hepatitis, chronic hepatitis or liver cirrhosis